Semaglutide is FDA-approved for long-term, ongoing use. There is no set time limit. The FDA’s indication for Wegovy specifically states it is meant to “reduce excess body weight and maintain weight reduction long-term,” and clinical guidelines treat obesity as a chronic condition requiring continuous management, much like high blood pressure or high cholesterol.
That said, “you can take it indefinitely” raises plenty of practical questions: what the long-term safety data actually shows, what happens if you stop, and whether your insurance will keep covering it. Here’s what the evidence says.
What Two Years of Clinical Data Shows
The longest dedicated weight-loss trial, known as STEP 5, followed participants on semaglutide 2.4 mg for 104 weeks (two years). People in the semaglutide group lost an average of 15.2% of their body weight, compared to 2.6% in the placebo group. Importantly, weight loss didn’t reverse over those two years. More than three-quarters of participants on semaglutide lost at least 5% of their starting weight by week 104, and about a third lost 20% or more.
Cardiovascular safety data extends even further. The SELECT trial, which studied semaglutide in people with obesity and heart disease, ran for over three years. Serious adverse events were actually lower in the semaglutide group than in the placebo group (33.4% vs. 36.4%), driven largely by fewer cardiac events. No new safety concerns emerged with extended use.
Side Effects Over the Long Term
Gastrointestinal symptoms, including nausea, diarrhea, and constipation, are the most common side effects and tend to be worst during the dose escalation phase. In the two-year trial, 82% of people on semaglutide reported GI side effects at some point, but the vast majority were mild to moderate. Only about 6% of participants stopped the medication because of side effects, a rate similar to placebo.
Gallbladder problems deserve attention during long-term use. In the SELECT trial, gallbladder-related disorders occurred in 2.8% of people on semaglutide versus 2.3% on placebo, with gallstones being the main driver. This is a known consequence of rapid weight loss regardless of how it happens, but it’s worth being aware of, especially in the first year when weight is dropping fastest. No cases of pancreatitis were reported in the two-year STEP 5 trial. Concerns about suicidal thoughts have not been supported by the data: rates of suicide or self-injury were identical in both groups at 0.11%.
Why Stopping Leads to Weight Regain
The clearest argument for long-term use comes from what happens when people stop. In an extension of the original STEP 1 trial, participants who discontinued semaglutide regained two-thirds of their prior weight loss within one year. On average, that meant gaining back about 12 percentage points of the weight they had lost.
This isn’t a failure of willpower. Semaglutide works by activating receptors in appetite-regulating areas of the brain, particularly the hypothalamus. When the drug is present, neurons in these regions fire in ways that reduce hunger even before you start eating, creating what researchers describe as “pre-ingestive satiation.” You feel satisfied sooner and think about food less. When the drug is removed, those signals return to their pre-treatment state, and appetite gradually climbs back to baseline. The body’s weight-regulating system treats the lost weight as a deficit to correct, which is why obesity is increasingly understood as a chronic condition rather than a problem you solve once.
The Dose Escalation Timeline
Before you reach the maintenance phase, there’s a 16-to-20-week ramp-up period. Treatment starts at 0.25 mg once weekly, then increases every four weeks through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the full maintenance dose of 2.4 mg. This gradual escalation exists to minimize nausea and other GI side effects. Most people reach the maintenance dose and stay there indefinitely.
Your prescriber may keep you at a lower dose if you’re responding well and tolerating it, though the 2.4 mg dose is what was studied in the major trials. Current guidelines recommend evaluating whether the medication is working for you after the initial escalation period and adjusting if needed, since individual responses vary considerably.
If You Decide to Stop
There are no formal clinical guidelines on how to taper off semaglutide. Some clinicians have adopted a gradual step-down over 8 to 12 weeks, reducing from 2.4 mg to 1.0 mg and then to 0.5 mg before stopping entirely. In clinical practice, this approach appears to result in more stable appetite regulation and a smoother transition, though this is based on clinical observation rather than randomized trial data. Stopping abruptly isn’t dangerous, but the return of appetite can feel abrupt.
Regardless of how you taper, the weight regain data suggests that without the medication, maintaining the full extent of your weight loss through lifestyle changes alone is difficult for most people. Some weight regain is likely, though people who have built strong exercise and dietary habits during treatment tend to retain more of their results.
Insurance and Continuation Requirements
Even though semaglutide is approved for indefinite use, your insurance may require periodic reauthorization. A common threshold for continued coverage is demonstrating at least 5% weight loss from your pre-treatment baseline. If you haven’t hit that mark, your insurer may deny renewal. These requirements vary by plan, so it’s worth understanding your specific policy’s criteria early in treatment rather than being surprised at the 6- or 12-month mark.
For people paying out of pocket, the cost of indefinite treatment is a significant consideration. Some people use semaglutide to reach a target weight and then attempt to maintain it through lifestyle modifications alone, accepting some degree of regain as a tradeoff. Others plan for long-term use from the start, budgeting accordingly.